TEVA PHARMA HOLDINGS LIMITED
Get an alert when TEVA PHARMA HOLDINGS LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Next accounts due
2026-09-30 (in 4mo)
Last filed for 2024-12-31
Confirmation statement due
2027-04-25 (in 11mo)
Last made up 2026-04-11
Watchouts
None on the register
Accounts
Audit & accounting basis
- Accounting basis
- FRS 102
- Reporting scope
- Standalone (parent only)
- Auditor
- Azets Audit Services Limited
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“The directors consider that preparing the financial statements on a going concern basis is appropriate due to the continued financial support of Teva Pharmaceuticals Europe B.V., a fellow group company. The directors have received confirmation from Teva Pharmaceuticals Europe B.V. that it has pledged its continuing support for a minimum of 12 months from the date of signing these financial statements.”
Group structure
- TEVA PHARMA HOLDINGS LIMITED · parent
- Arrow Generics Limited 100%
- Breath Limited 100%
- Cephalon (UK) Limited 100%
- Norton Healthcare Limited 100%
- Pliva Pharma Limited 100%
- Teva Laboratories UK Limited 100%
- Teva Pharmaceuticals Limited 100%
- Teva UK Limited 100%
- Teva UK Holdings Limited 100%
Significant events
- “On 5 November 2024 the company's directly owned subsidiary, Teva UK Holdings Limited, transferred its fully-owned subsidiaries Cephalon (UK) Limited, Norton Healthcare Limited, Pliva Pharma Limited, Teva Pharmaceuticals Limited and Teva UK Limited to the company.”
- “The company's previously dormant subsidiaries, Arrow No 7 Limited and Bowmed Limited were dissolved on 2 December 2024.”
- “On 29 February 2024, the company reduced its share capital from £311,983,396 to £1 and transferred the realised reserve thereby arising to profit and loss account reserves.”
- “On the same date, the company received a dividend of £152,786,000 (2023: £nil) from Teva UK Holdings Limited, which was partially used by the company to repay the total of the amounts due to a fellow group undertaking, Teva Finance Services II B.V. (TFS II), under a revolving credit agreement with the remainder transferred to the company's deposit agreement with TFS II.”
- “On 3 April 2024, the company entered into a series of intra-group transactions to simplify a number of intercompany balances within the company and the wider group, and this had the effect on Teva Pharma Holdings Limited as described below...”
- “On 19 November 2024, the company received dividends of £58,000,000 and £94,000,000 from Teva UK Limited and Teva Laboratories UK Limited respectively.”
- “On 19 March 2025, the company's wholly-owned direct subsidiary company, Piva Pharma Limited, assigned a receivable balance of £4,905,000 owed by a fellow group undertaking, Teva UK Limited, to the company, in consideration for an interest-free receivable of the same amount.”
- “Thereafter on the same date, Teva UK Limited settled the £9,589,000 amount that it owed to the company resulting from the above transactions, and then a dividend of £9,589,000 was paid by the company to its immediate parent company, Teva Pharmaceuticals Europe B.V. (TPE), representing an amount of £9,589,000/share.”
- “Following these transactions, the directors concluded that the carrying amount of the company's investment in Pliva Pharma Limited exceeded its recoverable amount and therefore an impairment charge of £224,000 was recognised.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
2 active · 6 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| CHARLESWORTH, Stephen Michael | Director | 2020-04-29 | Feb 1967 | British |
| INNES, Kim | Director | 2016-09-27 | Aug 1968 | British |
Show 6 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| PINSENT MASONS SECRETARIAL LIMITED | Corporate Secretary | 2017-03-13 | 2017-03-13 |
| COOPER, Dean Michael | Director | 2018-07-12 | 2020-04-29 |
| DANIELL, Richard Gordon | Director | 2016-04-12 | 2016-09-27 |
| SCHREWE, Michael | Director | 2016-04-12 | 2016-08-01 |
| VRHOVEC, David | Director | 2016-05-01 | 2026-01-01 |
| WILLIAMS, Robert | Director | 2016-04-12 | 2018-06-27 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Teva Pharmaceuticals Industries Limited | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2016-04-12 | Active |
Filing timeline
Last 20 of 42 total filings
Material constitutional events — rename, articles re-file, resolution
- 2024-03-06 RESOLUTIONS Resolution
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-04-13 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2026-01-05 | TM01 | officers | Termination director company with name termination date | |
| 2025-10-06 | AA | accounts | Accounts with accounts type full | |
| 2025-04-14 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2024-08-08 | AA | accounts | Accounts with accounts type full | |
| 2024-04-11 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2024-03-12 | SH19 | capital | Capital statement capital company with date currency figure | |
| 2024-03-06 | SH20 | capital | Legacy | |
| 2024-03-06 | CAP-SS | insolvency | Legacy | |
| 2024-03-06 | RESOLUTIONS | resolution | Resolution | |
| 2023-08-07 | AA | accounts | Accounts with accounts type full | |
| 2023-04-11 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2022-09-26 | AA | accounts | Accounts with accounts type full | |
| 2022-04-11 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2021-10-03 | AA | accounts | Accounts with accounts type full | |
| 2021-04-27 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2021-04-15 | CH01 | officers | Change person director company with change date | |
| 2021-04-15 | CH01 | officers | Change person director company with change date | |
| 2020-11-09 | AA | accounts | Accounts with accounts type full | |
| 2020-04-29 | TM01 | officers | Termination director company with name termination date |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 3
- Capital events
- 0
- Officers appointed
- 0
- Officers resigned
- 1
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.
Year-on-year
Latest filed period vs the prior one